Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System

Memorial Sloan Kettering Cancer Center (MSK)

Status: Completed

Conditions: Breast Cancer; Lung Cancer; Colorectal Cancer

Treatments: Behavioral: Focus groups

Study type: Observational

Funder types: Other

Identifiers

NCT02565017

15-226

Details and patient eligibility

About

The purpose of this study is to learn what cancer patients think about IBM Watson Oncology. IBM Watson Oncology is a computer program designed to help inform oncologists about the best chemotherapy choices for their patients. The investigators will conduct focus groups with cancer patients who have received chemotherapy treatment at MSK in order to understand cancer patients' thoughts about IBM Watson Oncology.

Enrollment: 70 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• MSKCC patient 18 years or older

• Breast, lung, or colorectal cancer MSK patient as per EMR or clinician judgment having either:

  • Chemotherapeutic adjuvant or neoadjuvant treatment with the first chemo visit occurring within the past 8 months and primary treatment (i.e., surgery), occurring within the past 6 months)at MSK
  • OR chemotherapeutic treatment for metastatic disease with the first chemo visit occurring within the past 8 months at MSK
  • OR chemotherapeutic treatment through an on-going MSK clinical trial as per clinician

• Residing in New York metro-area

Exclusion criteria

• Non-English speakers because we do not have the resources to conduct and translate the focus groups into other languages
• Patients who are not or will not receive their cancer care at MSKCC.
• Patient unwilling or unable to provide informed consent

Trial design

70 participants in 3 patient groups

Breast Cancer

Description:

and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).

Treatment:

Behavioral: Focus groups

Lung Cancer

Description:

and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).

Treatment:

Behavioral: Focus groups

Colorectal Cancer

Description:

and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).

Treatment:

Behavioral: Focus groups